Phoebe Sedgman

Mar 22, 2024 | bloomberg.com | Phoebe Sedgman

Boeing Co. is seeking a court order to block further use of its trade secrets by Virgin Galactic after the companies stopped working together on a space tourism project. The proprietary data was shared with Virgin Galactic when it engaged Boeing’s Aurora Flight Sciences unit to help develop a so-called Mothership jet carrier.

Mar 22, 2024 | flipboard.com | Phoebe Sedgman

2 days agoKate Winslet and Edward Abel Smith have been together since 2011, having met and married in just over a year. They keep the day-to-day of their life with their one son fairly private, but Smith has apparently been a huge support to Winslet in her successful career over the last 13 years. Here’s …

Feb 28, 2024 | bloomberg.com | Phoebe Sedgman

Shiseido Co. is offering early retirement for around 1,500 positions in Japan as the skincare firm seeks to boost growth and profitability. The plan will be offered to employees who meet certain age and tenure requirements, and applications will be open April 17 through May 8, the company said in a statementBloomberg Terminal Thursday. The estimated financial impact of the measure has already been incorporated into its full-year forecast, it said.

Jan 22, 2024 | news.bloomberglaw.com | Phoebe Sedgman

<-bsp-bb-link state="{"bbHref":"bbg://securities/SQ%20FP%20Equity/FA","_id":"0000018d-35d6-de1f-adbf-35fe80070000","_type":"0000016b-944a-dc2b-ab6b-d57ba1cc0000"}">Sanofi-bsp-bb-link> agreed to buy the US biotech <-rte-company state="{"_id":"0000018d-35d6-de1f-adbf-35fe80080000","_type":"00000160-4b23-d8bd-adfd-4b3348fd0000"}">Inhibrx Inc.-rte-company> for as much as $2.2 billion, giving the French drugmaker a potential therapy for a genetic disorder that affects the lungs and liver.

Jan 22, 2024 | bnnbloomberg.ca | Phoebe Sedgman

(Bloomberg) -- Sanofi will buy Inhibrx Inc. for as much as $2.2 billion, giving the French pharmaceutical firm ownership of a potential therapy for an inherited genetic condition called Alpha-1 Antitrypsin Deficiency. Inhibrx shareholders will get $30 per share and the right to receive a contingent payment of $5 in cash upon the achievement of a regulatory milestone, and one share of the ‘New Inhibrx’ for every four shares they hold currently, the companies said in a statement.